Skip to main content
. 2023 Nov 23;28(47):2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187

Figure 2.

Exclusions, I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, Europe, 2021–2022 (n = 8,093)

I-MOVE: Influenza – Monitoring Vaccine Effectiveness in Europe; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VEBIS: Vaccine Effectiveness, Burden and Impact Studies.

Included data are from 40 hospitals in 11 participating sites.

Figure 2